Why BD’s Wellstar partnership could reshape medication delivery inside hospitals
Hospitals need safer medication delivery, not more disconnected tech. BD and Wellstar are testing whether AI can close that workflow gap.
Hospitals need safer medication delivery, not more disconnected tech. BD and Wellstar are testing whether AI can close that workflow gap.
ECMO transport is a clinical weak point. Medtronic’s VitalFlow CE mark tests whether device mobility can strengthen critical care networks.
Microsure has European clearance for MUSA-3. Now hospitals must decide whether robotic microsurgery can justify adoption.
Wearable CGMs dominate diabetes care. Glucotrack’s implantable CBGM now faces the harder FDA test: durable blood-based proof.
Bladder testing needs better real-world data. Bright Uro’s FDA-cleared sensor may push urodynamics beyond catheter-heavy workflows.
Heart failure care needs faster decongestion without kidney harm. Reprieve’s FASTR data now face the pivotal trial test.
TriSalus has a delivery thesis, not just a device story. PREDICTT will test whether PEDD can make Y90 liver tumor therapy more precise.
Breast cancer surgery still struggles with missed margins. Cairn Surgical’s trial raises a sharper question for wire localization.
Pancreatic cancer needs local precision. Vector Science is betting a catheter patent can move drug delivery closer to the tumor.
Retina drugs are improving, but delivery remains the bottleneck. Everads Therapy is testing whether suprachoroidal access can change that.